This week, Bristol-Myers Squibb Company announced new data on the investigational anti-IL-6 antibody clazakizumab in adult patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate will be highlighted at the 2013 annual meeting of the American College of Rheumatology (ACR), taking place from October 25-30 in San Diego, Calif.
This asset was developed by Alder Biopharmaceuticals, and partnered with Bristol-Myers Squibb in 2009 in a deal worth $85 million up front and an additional $764 million in potential milestone payments. The therapeutic was developed using Alder’s yeast-based production technology, Mab Xpress, which enables the production of high quantities of antibodies.
Alder’s technology allows this class of therapeutics to enter disease areas that have previously been inaccessible for antibodies, such as migraine and cardiovascular disease. Alder is advancing an antibody therapeutic developed using this technology, ALD403, which targets the calcitonin gene-related peptide (CGRP) and holds promise for treating…
View original post 41 more words
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....
